Royalty Pharma plc (NASDAQ:RPRX) Receives $41.67 Average PT from Analysts

Shares of Royalty Pharma plc (NASDAQ:RPRX) have been given an average rating of “Moderate Buy” by the six analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $41.67.

Several research firms have issued reports on RPRX. Citigroup dropped their price target on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Morgan Stanley increased their price target on Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, July 11th. The Goldman Sachs Group boosted their price objective on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Finally, StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday.

Hedge Funds Weigh In On Royalty Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. increased its stake in shares of Royalty Pharma by 98.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 10,947 shares of the biopharmaceutical company’s stock worth $308,000 after purchasing an additional 5,438 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Royalty Pharma by 4,335.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,750 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 2,688 shares in the last quarter. New Century Financial Group LLC acquired a new stake in shares of Royalty Pharma in the first quarter worth about $1,091,000. Principal Financial Group Inc. boosted its stake in shares of Royalty Pharma by 34.6% during the 1st quarter. Principal Financial Group Inc. now owns 31,485 shares of the biopharmaceutical company’s stock worth $956,000 after acquiring an additional 8,086 shares in the last quarter. Finally, Capstone Investment Advisors LLC acquired a new position in shares of Royalty Pharma during the 1st quarter valued at about $542,000. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Trading Up 0.4 %

NASDAQ RPRX opened at $27.20 on Tuesday. The firm has a market capitalization of $16.14 billion, a PE ratio of 24.07, a price-to-earnings-growth ratio of 3.99 and a beta of 0.47. Royalty Pharma has a one year low of $25.20 and a one year high of $31.66. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35. The company has a 50-day simple moving average of $27.95 and a 200-day simple moving average of $27.56.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. The company had revenue of $537.00 million during the quarter, compared to analyst estimates of $600.83 million. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. During the same quarter in the previous year, the firm posted $0.85 EPS. On average, equities analysts forecast that Royalty Pharma will post 4.05 earnings per share for the current year.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.21 per share. The ex-dividend date is Friday, November 15th. This represents a $0.84 annualized dividend and a dividend yield of 3.09%. Royalty Pharma’s dividend payout ratio is 74.34%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.